Pharming Group N.V. Files 6-K with Press Release

TL;DR

Pharming Group N.V. dropped a 6-K with a press release on May 8th - check Exhibit 99.1 for details.

AI Summary

Pharming Group N.V. filed a Form 6-K on May 8, 2024, to furnish a press release dated May 8, 2024. The filing itself does not contain specific financial figures or operational details beyond referencing the attached press release as Exhibit 99.1.

Why It Matters

This filing indicates that Pharming Group N.V. is providing updated information to the SEC, likely containing material news for investors that is detailed in the accompanying press release.

Risk Assessment

Risk Level: low — The filing is a routine submission of a press release and does not contain inherently risky information itself.

Key Players & Entities

• Pharming Group N.V. (company) — Registrant
• May 8, 2024 (date) — Filing and Press Release Date
• 001-39822 (other) — Commission File Number
• Exhibit 99.1 (other) — Attached Press Release

FAQ

From the Filing

0001828316-24-000020.txt : 20240508 0001828316-24-000020.hdr.sgml : 20240508 20240508060447 ACCESSION NUMBER: 0001828316-24-000020 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240508 FILED AS OF DATE: 20240508 DATE AS OF CHANGE: 20240508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 24924064 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 a2024q1pressrelease.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated May 8, 2024. 1 EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group reports first quarter 2024 financial results SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s/ Sijmen de Vries Name: Sijmen de Vries Title: CEO Date: May 8, 2024 2 Pharming Group reports first quarter 2024 financial results and provides business update • First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja® and revenue growth of RUCONEST® • RUCONEST® revenues increased by 8% to US$46.0 million, compared to the first quarter 2023 • Joenja® (leniolisib) revenue of US$9.6 million, a 21% increase compared to the fourth quarter of 2023 • On track for 2024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth) • Overall cash and marketable securities of US$203.5 million at the end of the quarter • Pharming to host a conference call today at 13:30 CEST (7:30 am EDT) Leiden, the Netherlands, May 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the three months ended March 31, 2024. Chief Executive Officer, Sijmen de Vries commented: “Pharming delivered a strong first quarter, increasing quarterly revenues by 31% year-over-year to US$55.6 million and keeping the Company on track for our 2024 total revenue guidance of US$280 - US$295 million. This revenue growth was driven primarily by the U.S. commercial launch of Joenja®, and we also delivered continued strong RUCONEST® revenue growth and new patient enrollments as well as the first material named patient program revenues for leniolisib for patients outside of th